EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...

Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...

The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...

This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of $7.9 billion ...

A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.

Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination ...

Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...

Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at ASCO 2026: Rahway, New Jersey Wednesday, May 13, 2026, 11:00 Hrs [IST ...